

Combining Sanford Arylations on Benzodiazepines with the Nuisance Effect

Raysa Khan,^a Sarote Boonseng,^a Paul D. Kemmitt,^b Robert Felix,^c Simon J. Coles,^d Graham J. Tizzard,^d Gareth Williams,^e Olivia Simmonds,^e Jessica-Lily Harvey,^e John Attack,^e Hazel Cox^a and John Spencer^{a,*}

^a Department of Chemistry, School of Life Sciences, University of Sussex, Falmer, BN1 9QJ, UK.

Email: j.spencer@sussex.ac.uk

^b AstraZeneca, Mereside Alderley Park, Macclesfield, SK10 4TG, UK.

^c Tocris Bioscience, the Watkins Building, Atlantic Road, Avonmouth, Bristol, BS11 9QD, UK.

^d UK National Crystallography Service, School of Chemistry, University of Southampton, Highfield, Southampton, SO17 1BJ, U.K.

^e Sussex Drug Discovery Centre, School of Life Sciences, University of Sussex, Falmer, BN1 9QJ, UK.

Received: ((will be filled in by the editorial staff))



Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/adsc.201#####>. ((Please delete if not appropriate))

Abstract. 5-Phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-ones react under palladium- and visible light photoredox catalysis, in refluxing methanol, with aryldiazonium salts to afford the respective 5-(2-arylphenyl) analogues. With 2- or 4-fluorobenzenediazonium derivatives, both fluoroaryl- and methoxyaryl- products were obtained, the latter resulting from a S_NAr on the fluorobenzenediazonium salt (“nuisance effect”). A computational DFT analysis of the palladium-catalysed and the palladium/ruthenium-photocatalysed mechanism for the functionalization of benzodiazepines indicated that in the presence of the photocatalyst the reaction proceeds via a low-energy SET pathway avoiding the high-energy oxidative addition step in the palladium-only catalysed reaction pathway.

Keywords: C-H activation; benzodiazepine; photocatalysis; palladacycle, DFT.

Introduction


There is a growing impetus for atom economical routes to high value end products employing late stage functionalization (LSF) processes^[1]. These are particularly desirable in medicinal chemistry since they increase diversity and chemical space and enable rapid SAR (structure activity relationship) and ADME-Tox (Absorption, distribution, metabolism, elimination-toxicity) feedback that is key to costly, high attrition, drug development. Late stage C-H activation is a powerful tool in generating novel compounds for biological evaluation^[2]. We recently described a palladium-catalyzed ortho-arylation of benzodiazepines employing iodonium salts in acetic acid under microwave irradiation^[3]. The harsh

conditions, relatively high commercial cost, and multistep synthesis of iodonium salts^[4] ($ArIAr^{+}$), coupled with a poor atom economy ($Ar-I$ is a byproduct) prompted us to consider a visible-light photocatalyzed Pd-mediated protocol involving diazonium salts^[5].

Results and Discussion

Our initial reaction trials were performed on the benzodiazepine **1a**, using the 2-fluorobenzenediazonium salt **2a** under reflux (external oil bath temperature set at 70⁰ C). To our surprise, in addition to the expected product **3a**, we were able to isolate the ether product **4a**. However, reaction of the 3-isomer **2b** led exclusively to the fluoroaryl derivative **3b**, whereas the 4-isomer **2c**


afforded a mixture of fluorobiaryl **3c** and methoxy product **4c** (Scheme 1). Repeating the reaction in ethanol led to the ethyl ether **4d**.



Scheme 1. Benzodiazepine library synthesis.


Characterization of **4c** was enabled by determination of its solid state x-ray structure^[6] (Scheme 1) and by its unequivocal synthesis starting from 4-methoxybenzenediazonium tetrafluoroborate **2d** (Table 1) where we found slightly better yields under reflux (Entry 1 vs. 2) compared to either ambient temperature or to the absence of photocatalyst (Entry 5). Moreover, a palladium catalyst was essential (Entry 4) for achieving a good yield. Microwave-mediated chemistry, in the absence of light and photocatalyst, gave little conversion of product.

Entry	Lamps 26W	Pd(OAc) ₂ (mol %)	Ru(bpy) ₃ Cl ₂ · 6H ₂ O (mol %)	Temp. (°C)	Conv. LC/MS (%)
1	Yes	10	2.5	rt	52
2	Yes	10	2.5	Reflux ^a	61
3	No	10	2.5	Reflux ^a	35
4	Yes	0	2.5	Reflux ^a	0
5	Yes	10	0	Reflux ^a	57
6	No	10	0	^b	20



^aExternal oil bath temperature; 70°C, ^b microwave (MW), 125 °C, 1h.

To explain the formation of the ether products we propose a competing S_NAr, termed “nuisance effect,” which has historically been observed for halogen-substituted benzenediazonium salts, given the strong electron withdrawing effects of the diazo group, notably operating on the 2- and 4-substituted isomers^[7]. Indeed, simple alcoholysis of compound **2c** was achieved in the appropriate alcohol solvent at 70°C (Scheme 2).




Scheme 2. “Nuisance effect” on diazonium salts.

Table 1. Synthesis of an anisole derivative.

The C-H activation reaction was also applied to aryldiazoniums incapable of undergoing such a F-substitution and, hence derivatives **4e-4i** were synthesized in good to excellent yields (Scheme 3). Indeed, yields tend to be either similar or higher than those reported for the corresponding reactions

involving iodonium salts, e.g. **4e** (60% vs. 56%), **4f** (54% vs. 35%), **4g** (71% vs. 55%) and **4i** (64% vs. 63%).



Scheme 3. Other arylated benzodiazepines.

In the synthesis of **4i**, relatively large amounts of the diarylated adduct **4i'** were also observed. Such diarylations were previously reported by us.^{3b}


The current and previous library of benzodiazepines (Scheme 1) was tested for GABA binding^[8]. None of the current benzodiazepines displayed any appreciable biological activity although 7-chloro-benzodiazepines, as expected, had reasonable activity, although were *ca.* 7-10 fold less active than nordazepam and diazepam controls (Entries 1 and 2 respectively, Table 2) and were not pursued any further.

Table 2. GABA activity of library.

Entry	Compound	mean Ki (nM)/ SEM (nM) vs. GABA.
1		51.62 ± 2.0
2		41.41 ± 4.9
3		373.45 ± 110.5


4		421.54 ± 86.1
5		303.25 ± 60.7
6		689.56 ± 480.3

Sanford et al. proposed a possible mechanism to explain their Pd/Ru photocatalysed C-H arylation^[5a]. Here we present a computational study of a Pd-catalysed and a Sanford-derived Pd/Ru photocatalysed mechanism for the functionalization of **1a** to **4g** (Scheme 4) to rationalise the increased yield in the presence of light and a Ru photocatalyst.



Scheme 4. The formation reaction of **4g** with (i) and without (ii) the Ru photocatalyst, investigated using DFT.

The detailed mechanism is shown in Scheme 5 and the reaction profile (relative to the reactants) in Figure 1. The reaction mechanism, with and without the Ru(II)-photocatalyst, essentially follows the same path except that the oxidative addition step in the presence of just the Pd(II)-catalyst (path shown in green, Scheme 5 and Figure 1), is replaced by a single-electron-transfer (SET) process when the Ru(II)-photocatalyst is added (shown in red, Scheme 5 and Figure 1).



Pd and the agostic H in **Int2** is 1.903 Å, which is in good agreement with similar agostic interactions in the literature: Pd---H = 1.91 Å^[9] and Rh---H (1.95 Å)^[10]. The barrier to C-H bond activation is 41.4 kJ mol⁻¹, and involves H migration from C to O *via* a six-membered ring (**TS2-3**). Prior to coordination with the *p*-nitrobenzenediazonium (Ar-N₂⁺) the complex undergoes an isomerisation step (**TS3-4**), which involves a change in the C1-Pd-O3 angle from 132.0 to 172.0 degrees with an energy barrier of 27.8 kJ mol⁻¹ to form **Int4**.

In the absence of the photocatalyst, Ar-N₂⁺ interacts with the Pd(II) complex and follows an oxidation addition (OA) pathway, (highlighted in green, Scheme 5 and Figure 1). The oxidative addition via **TS5-6(OA)** has an energy barrier of 127.1 kJ mol⁻¹ and involves the formation of an Ar-Pd(IV) complex. The N₂ is then eliminated leading to **Int7**.


When the Ru(II)-photocatalyst is present, the nitrobenzene radical (Ar^*) is generated from Ar-N_2^+ (via oxidative quenching of Ar-N_2^+ by the photo-excited $[\text{Ru}(\text{bpy})_3]^{2+}$ complex to form $[\text{Ru}(\text{bpy})_3]^{3+[\text{11}]}$ and follows a single-electron-transfer (SET) pathway, (in red, Scheme 5 and Figure 1). The square planar geometry of the Pd(II) complex **Int4** becomes a Pd(III) distorted-octahedral structure when the Ar binds to the Pd centre in **Int5(SET)**; this is consistent with the crystal structure of other Pd(III)-complexes although we did not consider bimetallic species^[12]. **Int7** is formed directly from **Int5(SET)** by the transfer of an electron to the $[\text{Ru}(\text{bpy})_3]^{3+}$ complex to recover the photocatalyst. The Gibbs free energy barrier for single electron transfer (SET) resulting in the formation of the Pd(IV) complex **Int7** was calculated to be 2.5 kJ mol^{-1} using Marcus and Savéant theory^[13]. The details of this calculation are provided in the Computational Method section. This

barrier is very small but similar to literature values that range from 0.4 – 15.1 kJ mol⁻¹.^[14]

Both mechanisms (OA and SET) result in the same Pd(IV) structure for **Int7**. At this stage reductive

calculations and in a palladium complex crystal structure.^[17]

It is clear from Figure 1 that in the presence of the Pd-catalyst, the oxidative addition step is rate



elimination occurs via **TS7-8** with a barrier of 43.2 kJ mol⁻¹. This step involves the formation of a C-C bond
Figure 1. The reaction energy profile for the formation of **4g** from **1a**, with (red path) and without (green path) a photocatalyst. Steps common to both mechanisms are shown in blue. [Ru²⁺] and [Ru³⁺] represent [Ru(bpy)₃]²⁺ and [Ru(bpy)₃]³⁺, respectively.

to facilitate the functionalization of the benzodiazepine and the oxidation state of the Pd-center changes from Pd(IV) to Pd(II) (**Int7** → **Int8**). The geometry **Int8**, involves an $\eta^2(\text{C}=\text{C})$ interaction with Pd. A similar interaction was observed by Ariafard et al.^[15] and Canty et al.^[16] in their DFT

determining with a considerable energy barrier. However, in the presence of both the Pd(II)-catalyst and the Ru(II)-photocatalyst this OA step, and hence

large energy barrier, is avoided as the reaction proceeds via a very low-energy single-electron-transfer process. This provides a rationale for the increased yield in the presence of a photocatalyst.

Conclusion

The C-H activation of benzodiazepines with 2- or 4-fluorobenzene diazonium salts under Pd catalysis with a Ru photocatalyst, in alcohol solvent, under reflux, leads to a mixture of both fluoroaryl and alkoxyaryl products. Reaction temperature is a key factor in determining the ratio of expected vs. “nuisance effect” (S_NAr) products. At ambient temperature trace amounts of the S_NAr product are detected whereas significant amounts can be obtained after prolonged heating under reflux. This process can also be extended to other aryl diazonium salts affording ortho-arylated benzodiazepines. These were tested for biological activity but were found to be significantly less active than e.g. nordazepam and diazepam controls. Density functional theory (DFT) has been used to provide a detailed mechanistic understanding of the functionalization of the benzodiazepines and to offer an explanation for the increased yield in the presence of a Ru(II)-photocatalyst. The Pd/Ru catalytic cycle follows the mechanism proposed by Sandford et al. ^[5a]. The increased yield in the visible-light photocatalysed Pd-mediated protocol is attributed to the transformation step leading to the formation of the Pd(IV) complex. In the presence of the photocatalyst the reaction proceeds via a low-energy SET pathway and avoids the high-energy oxidative addition step in the Pd-only catalysed reaction pathway.

Current studies are aiming to extend the arylation/nuisance effect chemistry to a wider scope of privileged structures with different nucleophiles for application in medicinal chemistry library generation and will be reported in due course.

Experimental Section

General Information

All reactions were conducted under an inert atmosphere unless specified otherwise. All commercially purchased materials and solvents were used without further purification unless specified otherwise.

NMR spectra were recorded on a Varian VNMRs 500 (1H : 500 MHz, ^{13}C : 126 MHz) spectrometer and prepared in deuterated solvents such as $CDCl_3$ and $DMSO-d_6$. 1H and ^{13}C chemical shifts were recorded in parts per million (ppm). Multiplicity of 1H -NMR peaks are indicated by s – singlet, d – doublet, dd – doublets of doublets, t – triplet, pt – pseudo triplet, q – quartet, m – multiplet and coupling constants are given in Hertz (Hz).

Electrospray ionisation – high resolution mass spectra (ESI-HRMS) were obtained using a Bruker Daltonics Apex III where Apollo ESI was used as the ESI source. All analyses were conducted by Dr A. K. Abdul-Sada at Sussex. The molecular ion peaks $[M]^+$ were recorded as mass to charge (m/z) ratio.

LC-MS spectra were acquired using a Shimadzu LC-MS 2020, on a Gemini 5 μm C18 110 Å column and percentage purities were run over 30 minutes in water/acetonitrile with 0.1% formic acid (5 min at 5%, 5%-95% over 20 min, 5 min at 95%) with the UV detector at 254 nm. Purifications were performed by flash chromatography on silica gel columns or C18 columns using a Combi flash RF 75 PSI, ISCO unit. The following CCDC deposition numbers have been obtained, in parentheses; for **4c** (1518056), **4d** (1551609) and **4h** (1551610).

4-Methoxybenzenediazonium tetrafluoroborate (2d)

A stirred suspension of 4-fluorobenzenediazonium tetrafluoroborate (0.10 g, 0.48 mmol) in methanol (2

mL) was heated at 70°C by using an external oil bath for 1 hour. The reaction was allowed to cool to ambient temperature and concentrated under reduced pressure. The residue was precipitated by the addition of diethyl ether and collected by filtration, affording **2d** as a white solid (0.090 g, 85%). The spectral data were concurrent with those reported.^[18]

4-Ethoxybenzenediazonium tetrafluoroborate (2e)

The reaction was conducted by the same procedure as for **2d** but ethanol (2 mL) was used instead of methanol and heated at 70°C for 1 hour. **2e** was obtained as a white solid (0.071 g, 63%). The spectral data were concurrent with those reported.^[19]

2-Methoxybenzenediazonium tetrafluoroborate (2f)

The reaction was conducted by the same procedure as for **2d** but 2-fluorobenzenediazonium tetrafluoroborate (0.10, 0.48 mmol) was used instead. **2f** was obtained as a white solid (0.073 g, 72%). The spectral data were concurrent with those reported.

5-(2'-Fluorobiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (3a); 5-(2'-methoxybiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (4a)

5-Phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one (0.070 g, 0.3 mmol), 2-fluorobenzenediazonium tetrafluoroborate (0.25 g, 1.20 mmol) and palladium (II) acetate (0.0067 g, 0.03 mmol) were suspended in degassed, anhydrous methanol (5 mL). Two fluorescent light bulbs (26 W) were placed on either side of the reaction vessel and the reaction mixture was heated at 70°C by using an external oil bath for 4 hours. The reaction was allowed to cool to ambient temperature, diluted with ethyl acetate (50 mL), washed with water (20 mL) and aqueous sodium sulphite (10%, 35 mL x 2). The layers were separated

and the combined aqueous layers were extracted with ethyl acetate (50 mL). Thereafter the combined organic layer was washed with brine (50 mL), dried (MgSO₄) and concentrated under reduced pressure. The resulting crude material was purified by reversed phase chromatography (water/acetonitrile with 0.1% formic acid, 5 min at 0%, 30%-90%). Starting material **1a** was recovered (0.014 g, 0.06 mmol). Two products were generated; **3a** was obtained as a white solid (0.022 g, 28%) and **4a** was obtained as a white solid (0.030 g, 37%). **3a**: The spectral data were concurrent with those reported.³ **4a**: ¹H-NMR (500 MHz) CDCl₃: δ = 7.98 (s, NH, 1H), 7.68 (d, ³J_{HH} = 7.0 Hz, ArH, 1H), 7.52 – 7.42 (m, ArH, 2H), 7.28 (d, ³J_{HH} = 8.0 Hz, ArH, 1H), 7.19 – 7.12 (m, ArH, 1H), 7.06 – 6.98 (m, ArH, 2H), 6.90 – 6.83 (m, ArH, 1H), 6.80 (d, ³J_{HH} = 7.5 Hz, ArH, 1H), 6.69 – 6.60 (m, ArH, 2H), 6.52 (d, ³J_{HH} = 8.0 Hz, ArH, 1H), 4.22 (s, COCH₂, 2H), 3.51 (s, O-CH₃, 3H). ¹³C-NMR (126 MHz) CDCl₃: δ = 173.1 (C=O), 171.1 (C=N), 156.1 (ArC), 140.8 (ArC), 139.0 (ArC), 137.4 (ArC), 131.3 (ArC), 131.5 (ArC), 131.4 (ArC), 131.1 (ArC), 130.3 (ArC), 129.8 (ArC), 129.6 (ArC), 129.3 (ArC), 128.9 (ArC), 127.7 (ArC), 123.3 (ArC), 120.3 (ArC), 120.2 (ArC), 110.0 (ArC), 56.7 (COCH₂), 55.3 (O-CH₃). HRMS-ESI (m/z) calculated for C₂₂H₁₈FN₂O₂ [+H]⁺: 343.1441, found: 343.1446. LCMS purity (UV) = 96 %, t_R 10.63 min.

5-(3'-Fluorobiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (3b)

The reaction was conducted on a 0.20 mmol scale by the same procedure as for **3a/4a** but 3-fluorobenzenediazonium tetrafluoroborate (0.17 g, 0.8 mmol) was used instead of 2-fluorobenzenediazonium tetrafluoroborate. Starting material, **1a** was recovered (0.010 g, 0.042 mmol) and **3b** was obtained as a white

solid (0.040 g, 77%). The spectral data were concurrent with those reported.

5-(4'-Fluorobiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (3c); 5-(4'-Methoxybiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (4c)

This reaction was conducted on a 0.42 mmol scale by the same procedure as **3a/4a** and 4-fluorobenzenediazonium tetrafluoroborate (0.35 g, 1.67 mmol) was used instead of 2-fluorobenzenediazonium tetrafluoroborate. Starting material, **1a** was recovered (0.015 g, 0.06 mmol) and the reaction generated two products; **3c** was obtained as a white solid (0.053 g, 45%) and **4c** was obtained as a white solid (0.038 g, 32%). **3c**: ¹H-NMR (500 MHz) DMSO-d₆: δ = 10.39 (s, ArH, 1H), 7.60 – 7.55 (m, 1H), 7.55 – 7.52 (m, ArH, 1H), 7.50 (d, ³J_{HH} = 7.5 Hz, ArH, 1H), 7.33 – 7.30 (m, ArH, 1H), 7.21 – 7.17 (m, ArH, 1H), 6.92 – 6.86 (m, ArH, 4H), 6.83 – 6.77 (m, ArH, 2H), 6.69 (d, ³J_{HH} = 8.0 Hz, 1H), 4.03 (s, COCH₂, 2H).

¹³C-NMR (126 MHz) DMSO-D₆: δ = 172.1 (C=O), 169.7 (C=N), 161.5 (d, ¹J_{FC} = 244.0 Hz, ArC), 140.4 (ArC), 139.8 (ArC), 139.2 (ArC), 136.9 (ArC), 131.5 (ArC), 130.4 (ArC), 130.5 (d, ³J_{FC} = 7.5 Hz, 2 x ArC), 130.2 (ArC), 130.1 (ArC), 129.3 (ArC), 128.3 (ArC), 127.8 (ArC), 122.7 (ArC), 120.7 (ArC), 114.9 (d, ²J_{FC} = 22.0 Hz, 2 x ArC), 57.3 (COCH₂). HRMS-ESI (m/z) calculated for C₂₁H₁₅FN₂O [⁺H]⁺: 331.1241, found: 331.1244. LCMS purity (UV) = 92%, tR 11.16 min. **4c**: The spectral data were concurrent with those reported.

5-(4'-Ethoxybiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (4d)

The same method as that of **3a/4a** was used but ethanol (5 mL) was used as the solvent instead of methanol. Starting material, **1a**, was recovered (0.020

g, 0.085 mmol). Two products were generated, product **3c** was obtained as a white solid (0.043 g, 39%) and Product **4d** was obtained as a white solid (0.026 g, 22%). **4d**: ¹H-NMR (500 MHz) CDCl₃: δ = 8.20 (s, NH, 1H), 7.68 (d, ³J_{HH} = 7.5 Hz, ArH, 1H), 7.57 – 7.38 (m, ArH, 2H), 7.28 (d, ³J_{HH} = 7.5 Hz, ArH, 1H), 7.15 (pt, ³J_{HH} = 7.5 Hz, ArH, 1H), 6.91 – 6.81 (m, ArH, 4H), 6.69 (d, ³J_{HH} = 8.0 Hz, ArH, 1H), 6.60 (d, ³J_{HH} = 8.0 Hz, ArH, 2H), 4.29 (s, COCH₂, 2H), 3.94 (q, ³J_{HH} = 7.0 Hz, O-CH₂CH₃, 2H), 1.36 (t, ³J_{HH} = 7.0 Hz, O-CH₂CH₃, 3H). ¹³C-NMR (126 MHz) CDCl₃: δ = 173.2 (C=O), 170.7 (C=N), 157.8 (ArC), 141.7 (ArC), 139.5 (ArC), 137.3 (ArC), 133.2 (ArC), 131.1 (ArC), 130.1 (ArC), 129.9 (ArC), 129.7 (ArC), 129.8 (2 x ArC), 129.5 (ArC), 129.1 (ArC), 128.1 (ArC), 126.9 (ArC), 123.1 (ArC), 113.8 (2 x ArC), 63.5 (O-CH₂CH₃), 56.5 (COCH₂), 14.8 (O-CH₂CH₃). HRMS-ESI (m/z) calculated for C₂₃H₂₀N₂O₂ [⁺Na]⁺: 379.1417, found: 379.1419. LCMS purity (UV) = 87 %, tR 10.89 min.

5-Phenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (4e)

The reaction was conducted by the same procedure as for **3a/4a** but benzenediazonium tetrafluoroborate (0.23 g, 1.20 mmol) was used instead of 2-fluorobenzenediazonium tetrafluoroborate. Starting material **1a** was recovered (0.016 g, 0.067 mmol) and **4e** was obtained as a white solid (0.043 g, 60%). All Spectral data were concurrent with those reported.

5-(4'-Methoxybiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (4f)

The reaction was conducted on a 0.32 mmol scale by the same procedure as for **3a/4a** but 4-methoxybenzenediazonium tetrafluoroborate (0.28 g, 1.28 mmol) was used instead of 2-fluorobenzenediazonium tetrafluoroborate. Starting

material, **1a** was recovered (0.015 g, 0.063 mmol) and **4f** was obtained as a white solid (0.048 g, 54%). All Spectral data were concurrent with those reported.

5-(4'-Nitrobiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (4g)

The reaction was conducted on a 0.45 mmol scale by the same procedure as for **3a/4a** but 4-nitrobenzenediazonium tetrafluoroborate (0.43 g, 1.80 mmol) was used instead. Starting material, **1a** was recovered (0.020 g, 0.085 mmol) and **4g** was obtained as a white solid (0.093 g, 71%). ¹H-NMR (500 MHz) CDCl₃: δ = 8.78 (s, 1H), 7.94 (dd, ³J_{HH} = 8.5, 1.5 Hz, 2H), 7.78 – 7.72 (m, 1H), 7.60 – 7.52 (m, 2H), 7.34 – 7.28 (m, 1H), 7.22 – 7.13 (m, 3H), 6.90 – 6.83 (m, 2H), 6.72 (d, ³J_{HH} = 8.0 Hz, 1H), 4.31 (s, COCH₂, 2H). ¹³C-NMR (126 MHz) CDCl₃: δ = 172.1 (C=O), 170.6 (C=N), 147.4 (ArC), 146.6 (ArC), 139.7 (ArC), 139.6 (ArC), 137.5 (ArC), 131.7 (ArC), 130.4 (ArC), 129.9 (ArC), 129.8 (ArC), 129.6 (ArC), 129.5 (ArC x 2), 128.7 (ArC), 128.6 (ArC), 123.3 (ArC), 122.7 (ArC x 2), 120.1 (ArC), 56.5 (COCH₂). HRMS-ESI (m/z) calculated for C₂₁H₁₅N₃O₃ [+H]⁺: 358.1186, found: 358.1191. Elemental Analysis: Calculated for C₂₁H₁₅N₃O₃ (%): C, 70.58, H, 4.23, N, 11.76, found: C, 70.41, H, 4.23, N, 11.60.

5-(4'-Bromobiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (4h)

The reaction was conducted on a 0.25 mmol scale by the same procedure as for **3a/4a** but 4-bromobenzenediazonium tetrafluoroborate (0.27 g, 1.0 mmol) was used instead. Starting material, **1a** was recovered (0.012 g, 0.051 mmol) and **4h** was obtained as a white solid (0.051 g, 65%). ¹H-NMR (500 MHz) DMSO-d₆: δ = 10.44 (s, 1H), 7.56 (pt, ³J_{HH} = 8.0 Hz, 2H), 7.54 – 7.48 (m, 1H), 7.34 (d, ³J_{HH} = 8.0 Hz, 1H), 7.28 (d, ³J_{HH} = 8.0 Hz, 2H), 7.23 (pt, ³J_{HH} = 7.5 Hz,

1H), 6.87 (dd, *J* = 8.0, 5.9 Hz, 3H), 6.82 (pt, ³J_{HH} = 7.5 Hz, 1H), 6.73 (d, ³J_{HH} = 8.0 Hz, 1H), 4.05 (s, COCH₂, 2H). ¹³C-NMR (126 MHz) DMSO-d₆: δ = 171.9 (C=O), 169.8 (C=N), 140.2 (ArC), 139.8 (ArC), 139.6 (ArC), 139.3 (ArC), 131.5 (ArC), 131.1 (ArC), 131.0 (ArC x 2), 130.6 (ArC x 2), 130.3 (ArC), 130.2 (ArC), 130.1 (ArC), 129.5 (ArC), 128.2 (ArC), 128.1 (ArC), 122.7 (ArC), 120.7 (ArC), 56.7 (COCH₂). HRMS-ESI (m/z) calculated for C₂₁H₁₅BrN₂O [+H]⁺: 391.0441, found: 391.0449. LCMS purity (UV) = 95 %, tR 14.56 min.

5-(3'-Trifluoromethylbiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (4i); 5-(3,3'-bistrifluoromethylbiphenyl-2,6-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (4i')

The reaction was conducted on a 0.39 mmol scale by the same procedure as for **3a/4a** but 3-trifluoromethylbenzenediazonium tetrafluoroborate (0.41 g, 1.56 mmol) was used instead. **4i** was obtained as a brown solid (0.094 g, 64%) and the bisarylated product, **4i'**, was obtained as a brown solid (0.061 g, 30%). **4i**: All spectral data were concurrent with those reported. **4i'**: ¹H-NMR (500 MHz) DMSO-d₆: δ = 10.01 (s, 1H), 7.66 (pt, ³J_{HH} = 7.5 Hz, 1H), 7.55 (d, ³J_{HH} = 8.0 Hz, 2H), 7.50 (d, ³J_{HH} = 7.5 Hz, 2H), 7.45 (pt, ³J_{HH} = 7.5 Hz, 2H), 7.41 – 7.36 (m, 4H), 7.22 – 7.18 (m, 1H), 6.96 – 6.89 (m, 2H), 6.75 (d, *J* = 8.0 Hz, 1H), 3.65 (s, COCH₂, 2H). ¹³C-NMR (126 MHz) CDCl₃: δ = 170.4 (C=O), 169.6 (C=N), 141.4 (ArC), 141.0 (ArC), 138.1 (ArC), 137.4 (ArC), 132.4 (ArC x 2), 131.7 (ArC), 130.1 (q, ²J_{FC}, 33 Hz, ArC x 2), 129.8 (ArC x 2), 129.4 (ArC x 2), 129.3 (ArC x 2), 128.7 (ArC), 128.2 (ArC x 2), 125.8 (q, ³J_{FC}, 3.5 Hz, ArC x 2), 123.9 (q, ³J_{FC}, 272.0 Hz ArC x 2), 123.7 (q, ³J_{FC}, 3.5 Hz, ArC x 2), 123.4 (ArC), 120.2 (ArC), 55.7 (COCH₂). C₂₉H₁₈F₆NO₂ [+H]⁺: 525.1396, found: 525.1402. LCMS purity (UV) = 98 %, tR 22.50 min.

Computational Details

Density functional theory (DFT) calculations were performed at the ω B97XD/6-311++G(2df,2p)[SDD]/PBE/6-31+G(d,p)[SDD] level of theory, using the Gaussian09 program^[20]. The Pople basis sets were used on all atoms except Pd and Ru for which the SDD relativistic effective core potentials were used^[21]. The PBE functional^[22] was used for the geometry optimisation and frequency analysis as it combines good accuracy for Pd complexes with computational speed^[23]. The long-range corrected hybrid functional ω B97XD^[24], which includes empirical dispersion corrections, was used for energies to ensure accurate energetics^[25]. Methanol solvent energy corrections were applied using the conductor-like polarisable continuum model (CPCM)^[26]. Accordingly, the Gibbs free energies presented in Figure 1 were obtained by adding the thermal free energy corrections obtained at the PBE/6-31+G(d,p)[SDD] level of theory to the solvent-corrected electronic energies obtained at the ω B97XD/6-311++G(2df,2p)[SDD] level of theory. All stationary states were verified as minima or transition states by the absence or presence, respectively, of a single imaginary vibrational frequency. Eigenvector following was used to ensure transition states connected the desired minima.

The Gibbs free energy barrier for single electron transfer (SET), ΔG_{ET}^\ddagger , was calculated using the following equation from Marcus and Savéant theory^[13b-d]:

$$\Delta G_{ET}^\ddagger = \Delta G_0^\ddagger \left[1 + \frac{\Delta G_r}{4\Delta G_0^\ddagger} \right]^2 \quad 1)$$

Here ΔG_r is the reaction energy for the electron transfer step and ΔG_0^\ddagger is the intrinsic barrier, which can be calculated as:

$$\Delta G_0^\ddagger = \frac{\lambda}{4} \quad 2)$$

In Eq. (2), λ is the reorganisation energy and consists of the inner reorganisation energy of the reactants, λ_i , and the solvent reorganisation energy, λ_o . For outer-sphere electron transfer as in the present case, λ_i is assumed to be zero (following literature precedents^[27]) thus λ is equal to λ_o .

The reaction energy for the electron transfer step ΔG_r is calculated as the energy of the reaction: Pd(III)-complex + [Ru(bpy)₃]³⁺ → Pd(IV)-complex + [Ru(bpy)₃]²⁺ (i.e. **Int5(SET)** to **Int7**, Scheme 5). The energy for this step is -83.4 kJ mol⁻¹.

The reorganisation energy $\lambda = \lambda_o$ is calculated using the following equation^[27-28]:

$$\lambda_o = \frac{N_A e^2}{4\pi\epsilon_0} \left(\frac{1}{\epsilon_{op}} - \frac{1}{\epsilon_s} \right) \left(\frac{1}{2r_1} + \frac{1}{2r_2} - \frac{1}{R} \right) \quad (3)$$

where N_A is the Avogadro constant (6.022×10²³ mol⁻¹), e is the electronic charge (1.602×10⁻¹⁹ C), ϵ_0 is the vacuum permittivity (8.854×10⁻¹² J⁻¹C²m⁻¹) and, ϵ_{op} and ϵ_s are the optical and static dielectric constant for solvent, respectively. For methanol, ϵ_{op} is 1.76 and ϵ_s is 32.613. r_1 , r_2 and R are the hard sphere radii of the donor, the acceptor, and their sum. In this work, the hard sphere radii approximation of [Ru(bpy)₃]³⁺ and the Pd(III)-complex (**Int5(SET)**) were calculated using the VOLUME keyword in Gaussian09. The calculated [Ru(bpy)₃]³⁺ radius is 6.18 Å and the calculated Pd(III)-complex radius is 6.47 Å. Using these values in Eq. (3) gives $\lambda_o = 59.1$ kJ mol⁻¹, and hence $\Delta G_0^\ddagger = 14.8$ kJ mol⁻¹. Substituting

these values for ΔG_0^\ddagger and ΔG_r in Eq. (1), provides a SET barrier, $\Delta G_{ET}^\ddagger = 2.5 \text{ kJ mol}^{-1}$.

Acknowledgements

EPSRC, AstraZeneca and Tocris are thanked for financial support (grant # EP/M507568/1). We would also like to thank the Royal Thai Government for the fully funded PhD scholarship awarded to SB and we acknowledge the use of the EPSRC UK National Service for Computational Chemistry Software (NSCCS) at Imperial College London in performing part of this work. We also thank the EPSRC UK National Mass Spectrometry Facility at Swansea University.

References.

- [1] T. Cernak, K. D. Dykstra, S. Tyagarajan, P. Vachal, S. W. Krska, *Chem. Soc. Rev.* **2016**, *45*, 546-576.
- [2] a) M. A. J. Duncton, *MedChemComm* **2011**, *2*, 1135; b) T. Gensch, M. N. Hopkinson, F. Glorius, J. Wencel-Delord, *Chem. Soc. Rev.* **2016**, *45*, 2900-2936; c) T. A. Bedell, G. A. Hone, D. Valette, J. Q. Yu, H. M. Davies, E. J. Sorensen, *Angew. Chem. Int. Ed. Engl.* **2016**, *55*, 8270-8274; d) A. Sharma, J. F. Hartwig, *Nature* **2015**, *517*, 600-604; e) J. J. Topczewski, P. J. Cabrera, N. I. Saper, M. S. Sanford, *Nature* **2016**, *531*, 220-224; f) L. McMurray, F. O'Hara, M. J. Gaunt, *Chem. Soc. Rev.* **2011**, *40*, 1885-1898; g) A. McNally, B. Haffemayer, B. S. Collins, M. J. Gaunt, *Nature* **2014**, *510*, 129-133; h) F.-L. Zhang, K. Hong, Tuan-Jie Li, H. Park, J.-Q. Yu, *Science* **2016**, *351*, 252-256; i) F. O'Hara, D. G. Blackmond, P. S. Baran, *J. Am. Chem. Soc.* **2013**, *135*, 12122-12134; j) O. Abdulla, A. D. Clayton, R. A. Faulkner, D. M. Gill, C. R. Rice, S. M. Walton, J. B. Sweeney, *Chem., Eur. J.* **2017**, *23*, 1494-1497; k) A. F. Noisier, M. A. Brimble, *Chem. Rev.* **2014**, *114*, 8775-8806; l) J. P. Barham, M. P. John, J. A. Murphy, *J. Am. Chem. Soc.* **2016**, *138*, 15482-15487; m) J. He, L. G. Hamann, H. M. Davies, R. E. Beckwith, *Nat. Commun.* **2015**, *6*, 5943; n) Q. Michaudel, G. Journot, A. Regueiro-Ren, A. Goswami, Z. Guo, T. P. Tully, L. Zou, R. O. Ramabhadran, K. N. Houk, P. S. Baran, *Angew. Chem. Int. Ed. Engl.* **2014**, *53*, 12091-12096; o) D. A. Nagib, D. W. MacMillan, *Nature* **2011**, *480*, 224-228; p) Y. Zhu, M. Bauer, L. Ackermann, *Chem. Eur. J.* **2015**, *21*, 9980-9983. q) F. Yang, J. Koeller, L. Ackermann, *Angew. Chem. Int. Ed.* **2016**, *55*, 4759-4762.
- [3] a) J. Spencer, B. Z. Chowdhry, A. I. Mallet, R. P. Rathnam, T. Adatia, A. Bashall, F. Rominger, *Tetrahedron* **2008**, *64*, 6082-6089; b) R. Khan, R. Felix, P. D. Kemmitt, S. J. Coles, I. J. Day, G. J. Tizzard, J. Spencer, *Adv. Synth. Catal.* **2016**, *358*, 98-109.
- [4] a) E. A. Merritt, B. Olofsson, *Angew. Chem. Int. Ed. Engl.* **2009**, *48*, 9052-9070; b) M. S. Yusubov, A. V. Maskae, V. V. Zhdankin, *Arkivoc* **2011**, *1*, 370-409; c) S. G. Modha, M. F. Greaney, *J. Am. Chem. Soc.* **2015**, *137*, 1416-1419.
- [5] a) D. Kalyani, K. B. McMurtrey, S. R. Neufeldt, M. S. Sanford, *J. Am. Chem. Soc.* **2011**, *133*, 18566-18569; b) J. Jiang, W. M. Zhang, J. J. Dai, J. Xu, H. J. Xu, *J. Org. Chem.* **2017**, *82*, 3622-3630; c) M. Majek, A. Jacobi von Wangelin, *Acc. Chem. Res.* **2016**, *49*, 2316-2327; d) L. Marzo, I. Ghosh, F. Esteban, B. König, *ACS Catal.* **2016**, 6780-6784; e) D. P. Hari, P. Schroll, B. König, *J. Am. Chem. Soc.* **2012**, *134*, 2958-2961.
- [6] S. J. Coles, P. A. Gale, *Chem. Sci.* **2012**, *3*, 683-689.
- [7] a) J. F. Bunnett, R. E. Zahler, *Chem. Rev.* **1951**, 273- 412; b) I. K. Barbem, H. Suschitz, *J. Chem. Soc.* **1960**, 2735-2739.
- [8] J. R. Attack, K. A. Wafford, S. J. Tye, S. M. Cook, B. Sohal, A. Pike, C. Sur, D. Melillo, L. Bristow, F. Bromidge, I. Ragan, J. Kerby, L. Street, R. Carling, J. L. Castro, P. Whiting, G. R. Dawson, R. M. McKernan, *J. Pharmacol. Exp. Ther.* **2006**, *316*, 410-422.
- [9] D. L. Davies, S. M. A. Donald, S. A. Macgregor, *J. Am. Chem. Soc.* **2005**, *127*, 13754-13755.

- [10] A. Vigalok, O. Uzan, L. J. W. Shimon, Y. Ben-David, J. M. L. Martin, D. Milstein, *J. Am. Chem. Soc.* **1998**, *120*, 12539-12544.
- [11] F. Teplý, *Collection Czech Chem. Comm.* **2011**, *76*, 859-917.
- [12] a) J. R. Khusnutdinova, N. P. Rath, L. M. Mirica, *J. Am. Chem. Soc.* **2010**, *132*, 7303–7305. b) David C. Powers and Tobias Ritter, *Nat. Chem.* **2009**, *1*, 302–309
- [13] a) R. A. Marcus, *Ann. Rev. Phys. Chem.* **1964**, *15*, 155-196; b) R. A. Marcus, *J. Chem. Phys.* **1956**, *24*, 966-978; c) R. A. Marcus, *J. Chem. Phys.* **1956**, *24*, 979-989; d) J.-M. Saveant, *J. Am. Chem. Soc.* **1987**, *109*, 6788-6795.
- [14] Q. Zhang, Z.-Q. Zhang, Y. Fu, H.-Z. Yu, *ACS Catal.* **2016**, *6*, 798-808.
- [15] A. Ariaifard, C. J. T. Hyland, A. J. Canty, M. Sharma, B. F. Yates, *Inorg. Chem.* **2011**, *50*, 6449–6457.
- [16] A. J. Canty, A. Ariaifard, M. S. Sanford, B. F. Yates, *Organometallics* **2013**, *32*, 544–555.
- [17] H. Ossor, M. Pfeffer, J. T. B. H. Jastrzebski, C. H. Stam, *Inorg. Chem.* **1987**, *26*, 1169-1117 1161.
- [18] a) P. Hanson, J. R. Jones, A. B. Taylor, P. H. Walton, A. W. Timms, *J. Chem. Soc. Perkin Trans. 2* **2002**, 1135-1150; b) B. Schmidt, R. Berger, F. Holter, *Org. Biomol. Chem.* **2010**, *8*, 1406-1414.
- [19] S. H. Korzeniowski, A. Leopold, J. R. Beadle, M. F. Ahern, W. A. Sheppard, R. K. Khanna, G. W. Gokel, *J. Org. Chem.* **1981**, *46*, 2153-2159.
- [20] M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, et. al., Gaussian Inc., Wallingford, CT, **2009**.
- [21] D. Andrae, U. HuBermann, M. Dolg, H. Stoll, H. PreuB, *Theor. Chim. Acta* **1990**, *77*, 123-141.
- [22] J. P. Perdew, K. Burke, M. Ernzerhof, *Phys. Rev. Lett.* **1997**, *77*, 1396.
- [23] a) S. Boonseng, G. W. Roffe, J. Spencer, H. Cox, *Dalton Trans.* **2015**, *44*, 7570-7577; b) P. Surawatanawong, M. B. Hall, *Organometallics* **2008**, *27*, 6222-6232.
- [24] J. D. Chai, M. Head-Gordon, *Phys. Chem. Chem. Phys.* **2008**, *10*, 6615-6620.
- [25] a) Y. Minenkov, G. Occhipinti, V. R. Jensen, *J. Phys. Chem. A* **2009**, *113*, 11833–11844; b) N. Sieffert, M. Buhl, *Inorg. Chem.* **2009**, *48*, 4622-4624; c) M. L. Laury, A. K. Wilson, *J. Chem. Theory Comput.* **2013**, *9*, 3939-3946; d) Y. Zhao, D. G. Truhlar, *J. Chem. Theory Comput.* **2011**, *7*, 669-676.
- [26] a) V. Barone, M. Cossi, *J. Phys. Chem. A* **1998**, *102*, 1995-2001; b) M. Cossi, N. Rega, G. Scalmani, V. Barone, *J. Comp. Chem.* **2003**, *24*, 669-681.
- [27] a) G. O. Jones, P. Liu, K. N. Houk, S. L. Buchwald, *J. Am. Chem. Soc.* **2010**, *132*, 6205–6213; b) C. Y. Lin, M. L. Coote, A. Gennaro, K. Matyjaszewski, *J. Am. Chem. Soc.*, *130*, 12762–12774.
- [28] R. A. Marcus, N. Sutin, *Biochimica et Biophysica Acta* **1985**, *811*, 265-322.

